Antibody designed to prevent clotting: Erik Westein and Christoph Hagemeyer explain their research

Heart attack and stroke remain the leading causes of mortality and morbidity worldwide. Current anti-thrombotic therapies still suffer from severe bleeding side effects which limit the use of higher doses. Dr Erik Westein and Associate Professor Christoph Hagemeyer are senior authors on a paper in Haematologica which describes how they designed a unique antibody which inhibits a blood-borne protein, Von Willebrand Factor, to prevent thrombosis (dangerous clotting) without preventing normal clotting, thereby reducing excess bleeding.
Story:
http://ccsmonash.blogspot.com/2020/09/antibody-engineered-to-prevent-clotting.html
Reference:
Thomas Hoefer, Akshita Rana, Be'eri Niego, Shweta Jagdale, Hugo J Albers, Elizabeth E Gardiner, Robert K Andrews, Andries D van der Meer, Christoph E Hagemeyer, and Erik Westein. Targeting shear gradient activated von Willebrand Factor by the novel single-chain antibody A1 reduces occlusive thrombus formation in vitro.
https://www.haematologica.org/article/view/haematol.2020.250761
Nanobiotechnology lab/Hagemeyer group:
https://www.monash.edu/medicine/ccs/blood-disease/research/hagemeyer

Видео Antibody designed to prevent clotting: Erik Westein and Christoph Hagemeyer explain their research канала Translational Medicine, Monash University